Bioequivalence studies in Europe

Bioequivalence studies are designed to show that two drugs are equivalent and substitutable. - But even though the medicines are replaceable, the providers of bioequivalence studies are not. Digna Tost, Department Manager of Bioanalysis of Small Molecules at Kymos, resumes why Kymos is the right partner for bioequivalence projects: "Our clients are looking for (...)

Read more

By |2022-06-28T14:32:30+02:00June 22nd, 2022|News|Comments Off on Bioequivalence studies in Europe

KYMOS SUPPORTS UKRAINIAN PEOPLE

From Kymos Group we have joined to the expressions of the international community condemning the military intervention of the Russian army against the Ukrainian population, as well as the demand for an end to the violence on Ukrainian territory, the escalation of the conflict and the recovery of the diplomatic channel and dialogue. Beyond words, (...)

Read more

By |2022-06-28T14:32:30+02:00June 14th, 2022|News|Comments Off on KYMOS SUPPORTS UKRAINIAN PEOPLE

Pharmaprogress – Bright lights are on the horizon

In 2023, Pharmaprogress will move into a more spacious, convenient, and state-of-the-art building in the Ancona area. Luca Gramaccioni, General Site Manager of Pharmaprogress, and his team are excited about having more room soon: "In 2001, Pharmaprogress was established in the current building. After 20 years the team increased from the original 6 to (...)

Read more

By |2022-06-28T14:32:31+02:00May 24th, 2022|News|Comments Off on Pharmaprogress – Bright lights are on the horizon

Dissolution testing for all dosage forms

In recent months, we unfortunately had to turn down repeated requests for dissolution tests for which we would have needed the Dissolution USP 4 CE 7smart device. This was neither satisfactory for our customers nor for us. We have taken this situation seriously and ated accordingly: A brand-new Dissolution USP 4 CE 7smart device will (...)

Read more

By |2022-06-28T14:32:31+02:00May 10th, 2022|News|Comments Off on Dissolution testing for all dosage forms

Prolytic and Aeterna Zentaris – 20 years of improving human health together

For almost 20 years, Kymos’ German subsidiary Prolytic has accompanied Aeterna Zentaris in its development of pharmaceutical and diagnostic products. Katrin Dorfmeyer, Head of Chromatography, at Prolytic, and Dr. Michael Teifel, CSO at Aeterna Zentaris, shed light on the interesting project of the growth hormone secretagogue macimorelin (Macrilen, Ghryvelin) which they have been working on (...)

Read more

By |2022-06-28T14:32:31+02:00March 22nd, 2022|News|Comments Off on Prolytic and Aeterna Zentaris – 20 years of improving human health together

Joan Puig de Dou president of CataloniaBio & HealthTech

We congratulate our CEO Joan Puig de Dou on his election as president of CataloniaBio & HealthTech. We also send our congratulations to Mariona Serra-Pagès (GoodGut), Marta Palicio (Werfen OEM) and Isabel Amat Riera (Reig Jofre), and all other newly elected board members on their election to the CataloniaBio Board of Directors. We wish them great success for their projects and their (...)

Read more

By |2022-06-28T14:32:31+02:00March 3rd, 2022|News|Comments Off on Joan Puig de Dou president of CataloniaBio & HealthTech

Quantifying Active Enzymes – A bioanalytical challenge

Lisa Hentschel, Master of Molecular Biosciences, started her career at Prolytic eight years ago as a technician in the ELISA team. Since 2017, she now leads the Biology Department and is a recognized expert in large molecule bioanalysis, ADA determination and enzyme activity measurement. Together with Dr Busch, COO at Eleva, she shares her (...)

Read more

By |2022-06-28T14:32:32+02:00February 22nd, 2022|News|Comments Off on Quantifying Active Enzymes – A bioanalytical challenge

Nucleic Acids: From Biological Underdog to Biotech Top Dog

The analysis of nucleic acids, especially in biological matrices, is one of the newest services offered by the Kymos Group and carried out at its German subsidiary Prolytic. Maria Fauth, Head of the Oligonucleotides Department, has dedicated her entire academic and corporate career to the research and analysis of nucleic acids. She and Dr. Janine (...)

Read more

By |2022-06-28T14:32:32+02:00February 3rd, 2022|News|Comments Off on Nucleic Acids: From Biological Underdog to Biotech Top Dog

Kymos and ISGlobal join efforts to STOP parasitic diseases in Africa

“Kymos is a group with the highest ethical standards. This is not a PR statement but our day-to-day philosophy” Dr. Carles Celma, Scientific Director at Kymos stresses. “It was our pleasure to take an active role in the STOP project for the treatment of intestinal parasites in developing countries as soon as ISGlobal approached us.” (...)

Read more

By |2022-06-28T14:32:32+02:00November 30th, 2021|News|Comments Off on Kymos and ISGlobal join efforts to STOP parasitic diseases in Africa

Exceptional CPHI keeps business running

Finally, after a two-year break, we were able to attend CPhI again and meet our contacts in person. Despite the pandemic, cancellations and against many odds, this CPHI far exceeded all our expectations, and we thank all our clients and partners, but also the organisers and our team, who faced the challenge and made CPHI (...)

Read more

By |2022-06-28T14:32:32+02:00November 18th, 2021|News|Comments Off on Exceptional CPHI keeps business running